Avion Signs an Exclusive License Agreement with ImmuPharma to Develop and Commercialize Lupuzor

 Avion Signs an Exclusive License Agreement with ImmuPharma to Develop and Commercialize Lupuzor

Avion Signs an Exclusive License Agreement with ImmuPharma to Develop and Commercialize Lupuzor

Shots:

  • Immuphrama to receive $70M milestones including $5M as regulatory & $65M as commercialization milestones and up to 17% royalties on pre-specified annual US sales targets. ImmuPharma retains all rights to commercialize Lupuzor outside the US and receives an additional $5M on approval of Lupuzor for each additional indication (Ex- Lupus)
  • Avion to get an exclusive right to co-develop Lupuzor and the molecule forigerimod, exclusive right to commercialize Lupuzor in the US. Avion will fund up to $25M in P-III study of Lupuzor with its anticipated onset in 2020, following the agreement of the trial design between Avion, ImmuPharma and the FDA
  • Additionally, the companies signed a trademark license agreement under which Avion has the right to use relevant trademarks for the development, manufacture and commercialization of products

Click here to­ read full press release/ article | Ref: ImmuPharma | Image: ImmuPharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post